sar425899 sanofi glp-1 glucagon dual agonist Current GLP-1, GIP, and receptor co-agonists in development Transforming obesity: The advancement of

At the cellular level, GLP-1 receptor activation appears to reduce the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), and interleukin-1 beta (IL-1)

This outcome also exceeded the weight loss observed in the active comparator group treated with liraglutide 3.0 mg, a once-daily GLP-1 RA (10.8% vs

In India, the drug can be prescribed only by endocrinologists, internal medicine specialists and cardiologists

Conclusions There is compelling evidence that metabolic diseases, including obesity, can adversely impact pregnancy outcomes

doi: 10.1038/s41467-023-39282-y [DOI] [PMC free article] [PubMed] [Google Scholar] 6